Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Nebulised BromAc in Healthy Volunteers
NCT05220605Phase 1Completed
- Sponsor
- Mucpharm
- Start
- Jul 2022
- Primary completion
- Aug 2022
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of bromelain and acetylcysteine inhalation solution in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Mucpharm. Primary endpoints: Safety of BromAc following nebulised delivery (Heart Rate), Safety of BromAc following nebulised delivery (Blood Pressure) and 4 more. Started Jul 2022; status: completed.
02
Drugs
bromelainacetylcysteine inhalation solution
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05220605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05220605.